28.43 USD
+0.21 (+0.74%)
28.13 USD
-0.3 (-1.06%)
We assign a fundamental rating of 4 out of 10 to ASTH. ASTH was compared to 101 industry peers in the Health Care Providers & Services industry. ASTH has a medium profitability rating, but doesn't score so well on its financial health evaluation. ASTH shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year ASTH was profitable.
In the past year ASTH had a positive cash flow from operations.
Each year in the past 5 years ASTH has been profitable.
ASTH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ASTH has a Return On Assets (0.43%) which is comparable to the rest of the industry.
ASTH has a Return On Equity of 1.23%. This is comparable to the rest of the industry: ASTH outperforms 56.44% of its industry peers.
ASTH has a Return On Invested Capital (2.95%) which is in line with its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ASTH is below the industry average of 9.21%.
The last Return On Invested Capital (2.95%) for ASTH is well below the 3 year average (7.07%), which needs to be investigated, but indicates that ASTH had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.43% | ||
| ROE | 1.23% | ||
| ROIC | 2.95% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
1.3 Margins
With a Profit Margin value of 0.33%, ASTH perfoms like the industry average, outperforming 50.49% of the companies in the same industry.
In the last couple of years the Profit Margin of ASTH has declined.
The Operating Margin of ASTH (2.59%) is comparable to the rest of the industry.
ASTH's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 10.25%, ASTH is doing worse than 73.27% of the companies in the same industry.
ASTH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.59% | ||
| PM (TTM) | 0.33% | ||
| GM | 10.25% |
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ASTH is destroying value.
The number of shares outstanding for ASTH has been increased compared to 1 year ago.
The debt/assets ratio for ASTH is higher compared to a year ago.
2.2 Solvency
ASTH has an Altman-Z score of 2.31. This is not the best score and indicates that ASTH is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.31, ASTH is in line with its industry, outperforming 52.48% of the companies in the same industry.
ASTH has a debt to FCF ratio of 10.83. This is a negative value and a sign of low solvency as ASTH would need 10.83 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 10.83, ASTH is in line with its industry, outperforming 42.57% of the companies in the same industry.
A Debt/Equity ratio of 1.29 is on the high side and indicates that ASTH has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.29, ASTH is doing worse than 64.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.29 | ||
| Debt/FCF | 10.83 | ||
| Altman-Z | 2.31 |
ROIC/WACC0.33
WACC8.86%
2.3 Liquidity
ASTH has a Current Ratio of 1.40. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
ASTH has a Current ratio (1.40) which is comparable to the rest of the industry.
A Quick Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
The Quick ratio of ASTH (1.40) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.4 |
3. Growth
3.1 Past
The earnings per share for ASTH have decreased strongly by -85.38% in the last year.
ASTH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.19% yearly.
Looking at the last year, ASTH shows a very strong growth in Revenue. The Revenue has grown by 68.17%.
Measured over the past years, ASTH shows a very strong growth in Revenue. The Revenue has been growing by 38.01% on average per year.
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%
3.2 Future
Based on estimates for the next years, ASTH will show a very strong growth in Earnings Per Share. The EPS will grow by 31.87% on average per year.
ASTH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.29% yearly.
EPS Next Y-43.43%
EPS Next 2Y19.69%
EPS Next 3Y29.02%
EPS Next 5Y31.87%
Revenue Next Year59.13%
Revenue Next 2Y41.37%
Revenue Next 3Y30.62%
Revenue Next 5Y18.29%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 149.63, which means the current valuation is very expensive for ASTH.
ASTH's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 27.19. ASTH is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 22.30 indicates a rather expensive valuation of ASTH.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ASTH is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.88, ASTH is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 149.63 | ||
| Fwd PE | 22.3 |
4.2 Price Multiples
ASTH's Enterprise Value to EBITDA ratio is in line with the industry average.
75.25% of the companies in the same industry are more expensive than ASTH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.71 | ||
| EV/EBITDA | 17.76 |
4.3 Compensation for Growth
A more expensive valuation may be justified as ASTH's earnings are expected to grow with 29.02% in the coming years.
PEG (NY)N/A
PEG (5Y)7.8
EPS Next 2Y19.69%
EPS Next 3Y29.02%
5. Dividend
5.1 Amount
ASTH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
28.43
+0.21 (+0.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners55.03%
Inst Owner ChangeN/A
Ins Owners9.86%
Ins Owner Change0.8%
Market Cap1.43B
Revenue(TTM)2.90B
Net Income(TTM)9.54M
Analysts85
Price Target38.42 (35.14%)
Short Float %7.63%
Short Ratio5.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP86.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73.24%
Min EPS beat(2)-97.78%
Max EPS beat(2)-48.7%
EPS beat(4)0
Avg EPS beat(4)-104%
Min EPS beat(4)-225.16%
Max EPS beat(4)-44.39%
EPS beat(8)4
Avg EPS beat(8)-42.64%
EPS beat(12)7
Avg EPS beat(12)-21.5%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.57%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.11%
PT rev (3m)-16.3%
EPS NQ rev (1m)-30.36%
EPS NQ rev (3m)-75.42%
EPS NY rev (1m)-16.19%
EPS NY rev (3m)-58.79%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)-5.38%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)-1.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 149.63 | ||
| Fwd PE | 22.3 | ||
| P/S | 0.49 | ||
| P/FCF | 14.71 | ||
| P/OCF | 13.39 | ||
| P/B | 1.84 | ||
| P/tB | N/A | ||
| EV/EBITDA | 17.76 |
EPS(TTM)0.19
EY0.67%
EPS(NY)1.27
Fwd EY4.48%
FCF(TTM)1.93
FCFY6.8%
OCF(TTM)2.12
OCFY7.47%
SpS57.74
BVpS15.46
TBVpS-7.43
PEG (NY)N/A
PEG (5Y)7.8
Graham Number8.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.43% | ||
| ROE | 1.23% | ||
| ROCE | 4.68% | ||
| ROIC | 2.95% | ||
| ROICexc | 4.15% | ||
| ROICexgc | N/A | ||
| OM | 2.59% | ||
| PM (TTM) | 0.33% | ||
| GM | 10.25% | ||
| FCFM | 3.35% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexgc growth 3Y-13.47%
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score3
Asset Turnover1.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.29 | ||
| Debt/FCF | 10.83 | ||
| Debt/EBITDA | 8.9 | ||
| Cap/Depr | 25.55% | ||
| Cap/Sales | 0.33% | ||
| Interest Coverage | 2.01 | ||
| Cash Conversion | 94.59% | ||
| Profit Quality | 1016.69% | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.4 | ||
| Altman-Z | 2.31 |
F-Score3
WACC8.86%
ROIC/WACC0.33
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
EPS Next Y-43.43%
EPS Next 2Y19.69%
EPS Next 3Y29.02%
EPS Next 5Y31.87%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%
Revenue Next Year59.13%
Revenue Next 2Y41.37%
Revenue Next 3Y30.62%
Revenue Next 5Y18.29%
EBIT growth 1Y-11.33%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year101.88%
EBIT Next 3Y45.68%
EBIT Next 5Y30.45%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A
ASTRANA HEALTH INC / ASTH FAQ
Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?
ChartMill assigns a fundamental rating of 4 / 10 to ASTH.
What is the valuation status of ASTRANA HEALTH INC (ASTH) stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Overvalued.
How profitable is ASTRANA HEALTH INC (ASTH) stock?
ASTRANA HEALTH INC (ASTH) has a profitability rating of 4 / 10.
What is the valuation of ASTRANA HEALTH INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ASTRANA HEALTH INC (ASTH) is 149.63 and the Price/Book (PB) ratio is 1.84.
Can you provide the financial health for ASTH stock?
The financial health rating of ASTRANA HEALTH INC (ASTH) is 3 / 10.